| scholarly article | Q13442814 |
| P2093 | author name string | Annette Bruchfeld | |
| Lars Ståhle | |||
| Magnus Söderberg | |||
| Karin Lindahl | |||
| Robert Schvarcz | |||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ribavirin | Q421862 |
| kidney disease | Q1054718 | ||
| P304 | page(s) | 1573-1580 | |
| P577 | publication date | 2003-08-01 | |
| P1433 | published in | Nephrology Dialysis Transplantation | Q15710302 |
| P1476 | title | Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency | |
| P478 | volume | 18 |
| Q92669598 | A brief history of the treatment of viral hepatitis C |
| Q38073147 | Antiviral therapy for HCV-associated cryoglobulinemic glomerulonephritis: case report and review of the literature. |
| Q56907510 | Chapter 16 Extrahepatic Manifestations in Patients with Chronic Hepatitis C Virus Infection |
| Q87393382 | Chapter 9: Infection-related glomerulonephritis |
| Q54989507 | Collapsing glomerulopathy as a complication of interferon therapy for hepatitis C infection |
| Q50551492 | Concentration-guided ribavirin dosing with darbepoetin support and peg-IFN alfa-2a for treatment of hepatitis C recurrence after liver transplantation |
| Q36739304 | Cryoglobulinaemic vasculitis: classification and clinical and therapeutic aspects |
| Q50571757 | Cryoglobulinemia in chronic hepatitis C: clinical aspects and response to treatment with interferon alpha and ribavirin |
| Q46911432 | De novo nephrotic syndrome following pegylated interferon alfa 2b/ribavirin therapy for chronic hepatitis C infection. |
| Q29619682 | Diagnosis, management, and treatment of hepatitis C: an update |
| Q37874043 | Effect of interferon-alpha-based antiviral therapy on hepatitis C virus-associated glomerulonephritis: a meta-analysis |
| Q46391838 | Factors accelerating liver fibrosis progression in renal transplant patients receiving ribavirin monotherapy for chronic hepatitis C. |
| Q34966853 | Hepatitis C and kidney disease: An overview and approach to management |
| Q34439125 | Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review |
| Q43157677 | Hepatitis C eradication and improvement of cryoglobulinemia-associated rash and membranoproliferative glomerulonephritis with interferon and ribavirin after kidney transplantation |
| Q36852123 | Hepatitis C in dialysis units: the Saudi experience |
| Q38552198 | Hepatitis C infection and chronic renal diseases |
| Q36496970 | Hepatitis C virus and its renal manifestations: a review and update |
| Q33801278 | Hepatitis C virus associated glomerulopathies |
| Q36852114 | Hepatitis C virus infection in dialysis patients |
| Q30486664 | Hepatitis C virus infection in nephrology patients |
| Q37057403 | Hepatitis C virus infection induced vasculitis |
| Q37288114 | Hepatitis C virus, cryoglobulinemia, and kidney: novel evidence |
| Q33363781 | Hepatitis C virus-associated extrahepatic manifestations: a review |
| Q33361560 | Hepatitis C virus-related extra-hepatic disease--aetiopathogenesis and management |
| Q38656396 | Introducing treat-to-target strategies of autoimmune extrahepatic manifestations of chronic hepatitis C virus infection |
| Q35128555 | Kidney transplantation from donors with hepatitis C infection. |
| Q36008973 | Life-Threatening Cryoglobulinemic Patients With Hepatitis C: Clinical Description and Outcome of 279 Patients |
| Q42844237 | Long term suppressive therapy with pegylated interferon for chronic hepatitis C associated membranoproliferative glomerulonephritis |
| Q38123558 | Long-term response to peginterferon in hepatitis C virus-associated nephrotic syndrome from focal segmental glomerulosclerosis |
| Q43974244 | Low glomerular filtration rate is a risk factor for ribavirin‐associated anaemia in old patients with chronic hepatitis C |
| Q82910548 | Management of hepatitis C in patients with chronic kidney disease |
| Q36379874 | Multiple-dose pharmacokinetics of peginterferon alfa-2b in patients with renal insufficiency |
| Q41504212 | Peg-IFN and ribavirin treatment for recurrence of genotype 2 and 3 hepatitis C after liver transplantation |
| Q42998971 | Pegylated interferon alpha-2b for patients with HCV recurrence and graft fibrosis following liver transplantation |
| Q42999766 | Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. |
| Q26781481 | Programmed death-1/programmed death-L1 signaling pathway and its blockade in hepatitis C virus immunotherapy |
| Q57945954 | References |
| Q38070957 | Remission of HCV-associated Glomerulonephritis with Pegylated IFN and Ribavirin Therapy after Liver Transplantation: Case Report and Literature Review |
| Q59049605 | Ribavirin at the Era of Novel Direct Antiviral Agents for the Treatment of Hepatitis C Virus Infection: Relevance of Pharmacological Monitoring |
| Q37019765 | SASLT practice guidelines: management of hepatitis C virus infection. |
| Q37335664 | Safety, tolerability, and pharmacokinetics of ribavirin in hepatitis C virus-infected patients with various degrees of renal impairment. |
| Q35835125 | Should patients with chronic hepatitis C infection be transplanted? |
| Q36775650 | Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy |
| Q58605407 | Successful recovery of associated interstitial nephritis and focal segmental glomerulosclerosis in patients with HCV and HIV treated with sofosbuvir and daclatasvir and revision of literature |
| Q42623529 | Systemic abnormalities in liver disease |
| Q45461798 | Systemic autoimmune diseases co-existing with chronic hepatitis C virus infection (the HISPAMEC Registry): patterns of clinical and immunological expression in 180 cases |
| Q59349554 | The association of hepatitis C infection with the onset of CKD and progression into ESRD |
| Q37634196 | The utility of therapeutic drug monitoring for ribavirin in patients with chronic hepatitis C--a critical review. |
| Q37837303 | Treatment issues surrounding hepatitis C in renal transplantation: A review |
| Q43038357 | Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha |
| Q34099424 | Treatment of hepatitis C virus infection |
| Q38544801 | Treatment of hepatitis C-related kidney disease |
| Q36412410 | Treatment of hepatitis C-virus-related glomerulonephritis. |
Search more.